Tallac Therapeutics

OverviewSuggest Edit

Tallac Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer patients. It produces immunotherapy candidates for multiple solid tumor malignancies using its Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. The company aims to create products that generate both an innate and adaptive immune response, which may produce a durable anti-cancer immunity.
TypePrivate
Founded2018
HQBurlingame, CA, US
Websitetallactherapeutics.com

Latest Updates

Employees (est.) (Jul 2021)12(+10%)
Cybersecurity ratingCMore

Key People/Management at Tallac Therapeutics

Hong I. Wan

Hong I. Wan

President, Chief Executive Officer and Co-Founder
Corey Goodman

Corey Goodman

Chairman and Co-Founder
Curtis Hecht

Curtis Hecht

Chief Business Officer
Jaume Pons

Jaume Pons

Co-Founder
Janet Sim

Janet Sim

Vice President, Biologics Discovery and Development
Bora Han

Bora Han

Vice President, Preclinical Development
Show more

Tallac Therapeutics Office Locations

Tallac Therapeutics has an office in Burlingame
Burlingame, CA, US (HQ)
866 Malcolm Rd #100
Show all (1)

Tallac Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Tallac Therapeutics total Funding

$83.2 m

Tallac Therapeutics latest funding size

$62 m

Time since last funding

8 months ago

Tallac Therapeutics investors

Tallac Therapeutics's latest funding round in December 2020 was reported to be $62 m. In total, Tallac Therapeutics has raised $83.2 m
Show all financial metrics

Tallac Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Tallac Therapeutics Online and Social Media Presence

Embed Graph

Tallac Therapeutics News and Updates

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

Tallac Therapeutics, Inc., a privately-held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing totaling $62 million

Tallac Therapeutics Frequently Asked Questions

  • When was Tallac Therapeutics founded?

    Tallac Therapeutics was founded in 2018.

  • Who are Tallac Therapeutics key executives?

    Tallac Therapeutics's key executives are Hong I. Wan, Corey Goodman and Curtis Hecht.

  • How many employees does Tallac Therapeutics have?

    Tallac Therapeutics has 15 employees.

  • Who are Tallac Therapeutics competitors?

    Competitors of Tallac Therapeutics include EMS Pharma, Biocon and Livzon Pharmaceutical Group.

  • Where is Tallac Therapeutics headquarters?

    Tallac Therapeutics headquarters is located at 866 Malcolm Rd #100, Burlingame.

  • Where are Tallac Therapeutics offices?

    Tallac Therapeutics has an office in Burlingame.

  • How many offices does Tallac Therapeutics have?

    Tallac Therapeutics has 1 office.